Palisade Bio (PALI) EBITDA (2010 - 2026)
Palisade Bio (PALI) posted quarterly EBITDA of -$10.7 million for Q1 2026, down 365.28% year-over-year from $4.1 million in Q1 2025, and down 7.68% quarter-over-quarter from -$10.0 million in Q4 2025.
Palisade Bio (PALI) EBITDA (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported EBITDA for 17 consecutive years, with -$10.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 365.28% year-over-year to -$10.7 million; the TTM figure through Mar 2026 stood at -$26.5 million (down 96.31% YoY), while the FY2025 annual figure was -$18.1 million, down 21.52% from the prior year.
- EBITDA retreated to -$10.7 million in Q1 2026 per PALI's latest filing, from -$10.0 million in the prior quarter.
- Across five years, EBITDA topped out at -$2.3 million in Q1 2025 and bottomed at -$10.7 million in Q1 2026.
- Historically, EBITDA has averaged -$4.3 million across 5 years, with a median of -$3.6 million in 2023.
- Annual changes were most pronounced in 2022 — EBITDA jumped 89.13% — and 2026, when it slumped 365.28%.
- Palisade Bio's EBITDA stood at -$3.8 million in 2022, then increased by 18.04% to -$3.2 million in 2023, then fell by 7.23% to -$3.4 million in 2024, then slumped by 195.12% to -$10.0 million in 2025, then fell by 7.68% to -$10.7 million in 2026.
- Business Quant data shows PALI's EBITDA at -$10.7 million in Q1 2026, -$10.0 million in Q4 2025, and -$2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | -11.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.70 Mn |
| Mar 31, 2026 | -10.75 Mn |
| Dec 31, 2025 | -9.98 Mn |
| Sep 30, 2025 | -2.92 Mn |
| Jun 30, 2025 | -2.84 Mn |
| Mar 31, 2025 | -2.31 Mn |
| Dec 31, 2024 | -3.38 Mn |
| Sep 30, 2024 | -3.59 Mn |
| Jun 30, 2024 | -4.21 Mn |
| Mar 31, 2024 | -3.67 Mn |
| Dec 31, 2023 | -3.15 Mn |
| Sep 30, 2023 | -3.78 Mn |
| Jun 30, 2023 | -3.61 Mn |
| Mar 31, 2023 | -2.53 Mn |
| Dec 31, 2022 | -3.85 Mn |
| Sep 30, 2022 | -4.41 Mn |
| Jun 30, 2022 | -3.57 Mn |
| Mar 31, 2022 | -3.89 Mn |
| Dec 31, 2021 | -4.03 Mn |
| Sep 30, 2021 | -3.02 Mn |